ZA200704928B - Formulations of human growth hormone comprising a non-naturally encoded amino acid - Google Patents
Formulations of human growth hormone comprising a non-naturally encoded amino acidInfo
- Publication number
- ZA200704928B ZA200704928B ZA200704928A ZA200704928A ZA200704928B ZA 200704928 B ZA200704928 B ZA 200704928B ZA 200704928 A ZA200704928 A ZA 200704928A ZA 200704928 A ZA200704928 A ZA 200704928A ZA 200704928 B ZA200704928 B ZA 200704928B
- Authority
- ZA
- South Africa
- Prior art keywords
- formulations
- amino acid
- growth hormone
- human growth
- encoded amino
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title 1
- 108010000521 Human Growth Hormone Proteins 0.000 title 1
- 239000000854 Human Growth Hormone Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63861604P | 2004-12-22 | 2004-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200704928B true ZA200704928B (en) | 2009-04-29 |
Family
ID=38943761
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200704928A ZA200704928B (en) | 2004-12-22 | 2005-12-21 | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| ZA200704924A ZA200704924B (en) | 2004-12-22 | 2005-12-21 | Methods for expression and purification of recombinant human growth hormone |
| ZA200704926A ZA200704926B (en) | 2004-12-22 | 2005-12-21 | Modified human growth hormone |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200704924A ZA200704924B (en) | 2004-12-22 | 2005-12-21 | Methods for expression and purification of recombinant human growth hormone |
| ZA200704926A ZA200704926B (en) | 2004-12-22 | 2005-12-21 | Modified human growth hormone |
Country Status (2)
| Country | Link |
|---|---|
| CN (3) | CN101356269A (en) |
| ZA (3) | ZA200704928B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG181769A1 (en) * | 2009-12-21 | 2012-07-30 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
| CN102062776A (en) * | 2010-12-16 | 2011-05-18 | 中华人民共和国天津出入境检验检疫局 | Babesia caballi disease immunoblotting detection method and preparation of kit |
| CN102838671B (en) * | 2011-06-23 | 2014-06-11 | 北京大学 | Growth hormone with site-specific mutagenesis and site-specific decoration, preparation method and applications of growth hormone |
| CN104245722A (en) * | 2012-02-29 | 2014-12-24 | Ambrx公司 | Interleukin-10 polypeptide conjugates and uses thereof |
| GB201303876D0 (en) * | 2013-01-29 | 2013-04-17 | Verenium Corp | Animal feed enzyme extraction |
| LT3849614T (en) * | 2018-09-11 | 2024-03-25 | Ambrx, Inc. | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USE |
| US20240317832A1 (en) * | 2021-07-29 | 2024-09-26 | Novocodex Biopharmaceuticals Co., Ltd. | Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate |
| CN113698468B (en) * | 2021-09-01 | 2022-10-11 | 浙江新码生物医药有限公司 | Human interleukin 2-polyethylene glycol conjugate and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| BRPI0507169A (en) * | 2004-02-02 | 2007-06-26 | Ambrx Inc | modified human growth hormone polypeptides and their uses |
-
2005
- 2005-12-21 ZA ZA200704928A patent/ZA200704928B/en unknown
- 2005-12-21 CN CNA2005800444637A patent/CN101356269A/en active Pending
- 2005-12-21 CN CN2005800444355A patent/CN101374536B/en not_active Expired - Fee Related
- 2005-12-21 ZA ZA200704924A patent/ZA200704924B/en unknown
- 2005-12-21 ZA ZA200704926A patent/ZA200704926B/en unknown
- 2005-12-21 CN CNA2005800444641A patent/CN101090980A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200704924B (en) | 2009-04-29 |
| CN101356269A (en) | 2009-01-28 |
| ZA200704926B (en) | 2008-12-31 |
| CN101374536A (en) | 2009-02-25 |
| CN101374536B (en) | 2013-09-25 |
| CN101090980A (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183345A0 (en) | Formulations of human growth hormone comprising a non-naturally encoded amino acid | |
| PL1817048T3 (en) | Stable formulations of insulinoptropic peptides | |
| IL181083A0 (en) | Synthetic hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | |
| IL177030A (en) | Use of d-arg-2',6'-dmt-lys-phe-nh2 for manufacturing a medicament for reducing oxidative damages in a mammal, peptides consisting of the amino acid sequence d-arg-2',6'-dmt-lys-phe-nh2 and compositions comprising them | |
| GB0520687D0 (en) | Skin treatment formulations | |
| IL183344A0 (en) | Methods for expression and purification of recombinant human growth hormone | |
| IL180739A0 (en) | Novel fenofibrate formulations and related methods of treatment | |
| WO2005072055A9 (en) | Novel brain natriuretic peptide variants and methods of use thereof | |
| EP1648416A4 (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them | |
| IL181348A0 (en) | Liquid preparation of physiologically active peptide | |
| AU2003279911A8 (en) | Therapeutic formulations | |
| EP1633851A4 (en) | Methods and compositions for amino acid production | |
| EP1675619A4 (en) | Sustained release l-arginine formulations and methods of manufacture and use | |
| ZA200704928B (en) | Formulations of human growth hormone comprising a non-naturally encoded amino acid | |
| EP1750767A4 (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them | |
| HUP0402334A3 (en) | Modified human growth hormone | |
| EP1740541A4 (en) | Therapeutic formulations of desoxyepothilones | |
| HK1116352A (en) | Formulations of human growth hormone comprising a non-naturally encoded amino acid | |
| EP1841444A4 (en) | Formulations of peptides for periodontal and dental treatments | |
| ZA200606224B (en) | Modified human growth hormone polypeptides and their uses | |
| EP1797888A4 (en) | Ophthalmic composition containing xanthan gum and amino acid | |
| ZA200701917B (en) | Novel fenofibrate formulations and related methods of treatment | |
| IL173194A0 (en) | Human growth hormone in parkinson-plus syndromes | |
| EP1713454A4 (en) | Enteric delivery of (-)-hydroxycitric acid | |
| ZA200706110B (en) | Pharmaceutical formulations of gallium salts |